Biogen and Swedish Orphan Biovitrum (Sobi) will jointly release data of the Phase III clinical extension studies, B-YOND and ASPIRE of Elocta and Alprolix, to treat haemophilia A and haemophilia B respectively.

Elocta (efmoroctocog alfa) is a recombinant clotting factor VIII therapy acting over a prolonged period in the body, while alprolix (eftrenonacog alfa) is also a recombinant clotting factor therapy indicated to be used for haemophilia B.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Haemophilia is a rarely occurring genetic disorder characterised by the inability to repair blood clot.

Patients afflicted with haemophilia A or B experience prolonged bleeding episodes causing pain, irreversible joint damage and life-threatening hemorrhages.

"Elocta and Alprolix are backed by robust clinical data and significant real-world experience."

Elocta treats haemophilia A by binding factor VIII to the Fc portion of protein immunoglobulin G subclass 1, or IgG1.

See Also:

It creates a natural pathway able to be used by Elocta for a prolonged operation in the body.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alprolix treats haemophilia B by binding factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 which creates a natural pathway to be used by Alprolix for an extended action within the body.

A post-hoc analysis of the studies intends to present a longitudinal evaluation of joint health from patients participating in A-LONG and ASPIRE studies, while target joint data gathered from the subset of patients involved in the B-LONG and B-YOND studies will also be presented at the WFH Congress.

Sobi haemophilia medical therapeutic area head and vice-president Krassimir Mitchev said: “Elocta and Alprolix are backed by robust clinical data and significant real-world experience.

“We believe these new data presentations will help healthcare providers to deepen their understanding of the clinical value and utility of these innovative medicines.”

The companies will also present preclinical pharmacokinetic data of recombinant FVIIIFc-VWF-XTEN, a fusion protein using XTEN technology to treat haemophilia A.